Pharmacological Characteristics of KP-102 (GHRP-2), a Potent Growth Hormone-Releasing Peptide

Summary KP-102 (D-alanyl-3-(2-naphthyl)-D-alanyl - L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide dihydrochloride, growth hormone-releasing peptide-2, GHRP-2, pralmorelin, CAS 158861-67-7), is a potent synthetic growth hormone (GH) secretagogue. In the present study, the pharmacological characteristics of the GH-releasing property of KP-102 were investigated by means of in vivo and in vitro experiments. In conscious rats, the GH-releasing activity of KP-102 was more potent than that of exogenously injected GH-releasing hormone (GHRH). Under pentobarbital anesthesia in which endogenous somatostatin secretion is known to be decreased, KP-102 and GHRH, both showed an almost equivalent GH-releasing potency, which was also similar to that of KP-102 in conscious rats. Besides, KP-102 showed GH-releasing activity in conscious dogs as well, while GHRH failed to increase serum GH levels in conscious dogs. These findings suggest that the GH-releasing activity of KP-102 was less sensitive to GH suppression by endogenous somatostatin as compared with that of GHRH. The GH-releasing activity of KP-102 was completely absent in hypophysectomized rats, but present in median eminencelesioned rats in which secreted GH amounts were significantly less than those in normal rats, indicating necessity of the median eminence (endogenous GHRH) to exert the full activity of KP-102 in GH stimulation. KP-102 directly stimulated GH secretion from cultured rat anterior pituitary cells, although the GH-releasing potency of KP-102 was significantly weaker than that of GHRH in vitro. In conscious rats, KP-102 stimulated the secretion of both adrenocorticotrophic hormone (ACTH) and corticosterone, but not of prolactin. Three weeks administration of KP-102 showed growth-accelerating effect, a slight increase of body weight and wet weight of some organs in both normal and monosodium glutamate (MSG)-treated rats. These results suggest that KP-102 showed specific GH-releasing activity apart from slight ACTH secretion, and that the GH-releasing activity was stable in comparison with that of exogenously injected GHRH.

[1]  O. Shimada,et al.  Morphological effects of somatostatin on rat somatotrophs previously activated by growth hormone-releasing factor , 1990, Cell and Tissue Research.

[2]  Noboru Murakami,et al.  The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. , 2002, Gastroenterology.

[3]  S. Toler,et al.  Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue. , 2001, Endocrine.

[4]  S. Bloom,et al.  The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. , 2000, Endocrinology.

[5]  M. Tschöp,et al.  Ghrelin induces adiposity in rodents , 2000, Nature.

[6]  M. Nakazato,et al.  Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. , 2000, Biochemical and biophysical research communications.

[7]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[8]  K. Raun,et al.  Pharmacological characterisation of a new oral GH secretagogue, NN703. , 1999, European journal of endocrinology.

[9]  G. Leng,et al.  An electrophysiological and morphological investigation of the projections of growth hormone-releasing peptide-6-responsive neurons in the rat arcuate nucleus to the median eminence and to the paraventricular nucleus , 1999, Neuroscience.

[10]  E. Arvat,et al.  Orally active growth hormone secretagogues: state of the art and clinical perspectives. , 1998, Annals of medicine.

[11]  S. Roh,et al.  Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells. , 1997, Journal of animal science.

[12]  Roy G. Smith,et al.  Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. , 1997, Brain research. Molecular brain research.

[13]  I. Robinson,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Activation of the Hypothalamo-Pituitary-Adrenal Axis by the Growth Hormone (GH) Secretagogue, GH-Releasing Peptide-6, in Rats , 2022 .

[14]  Patrick R. Griffin,et al.  A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.

[15]  H. Okamura,et al.  Effects of the synthesized growth hormone releasing peptide, KP-102, on growth hormone release in sodium glutamate monohydrate-treated low growth rats. , 1996, Life sciences.

[16]  S. Roh,et al.  Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves. , 1996, Endocrine journal.

[17]  C. Bowers,et al.  GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers , 1995, Clinical endocrinology.

[18]  D. Johnston,et al.  Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Steiger,et al.  Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. , 1995, Neuroendocrinology.

[20]  H. Sugihara,et al.  Effect of d-Ala-d-βNal-Ala-Trp-d-Phe-Lys-NH2 (KP-102) on GH secretion in urethan-anesthetized rats , 1994, Regulatory Peptides.

[21]  K. Takekoshi,et al.  [Measurements of serum pituitary hormones and dynamic tests to evaluate the pituitary functions]. , 1993, Nihon rinsho. Japanese journal of clinical medicine.

[22]  M. Fisher,et al.  Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue. , 1993, Endocrinology.

[23]  I. Robinson,et al.  Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons , 1993, Neuroscience.

[24]  C. Bowers.  GH Releasing Peptides - Structure and Kinetics , 1993, The Journal of pediatric endocrinology.

[25]  J. Devesa,et al.  Neuroendocrine control of growth hormone secretion in humans , 1992, Trends in Endocrinology & Metabolism.

[26]  T. Badger,et al.  On the actions of the growth hormone-releasing hexapeptide, GHRP. , 1991, Endocrinology.

[27]  G. Tannenbaum,et al.  Interplay of somatostatin and growth hormone-releasing hormone in genesis of episodic growth hormone secretion. , 1990, Metabolism: clinical and experimental.

[28]  T. Abribat,et al.  Growth hormone response induced by synthetic human growth hormone-releasing factor (1-44) in healthy dogs. , 1989, Zentralblatt fur Veterinarmedizin. Reihe A.

[29]  R. Clark,et al.  Growth hormone responses to multiple injections of a fragment of human growth hormone-releasing factor in conscious male and female rats. , 1985, The Journal of endocrinology.

[30]  F. Momany,et al.  Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides. , 1984, Endocrinology.

[31]  F. Momany,et al.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.

[32]  N. Ling,et al.  The absence of an age-related change in the pituitary response to growth hormone-releasing factor in rats. , 1983, Neuroendocrinology.

[33]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[34]  K. Chihara,et al.  Immunoreactive somatostatin in rat hypophyseal portal blood: effects of anesthetics. , 1979, Endocrinology.

[35]  J. Willoughby,et al.  Neuroendocrine organization of growth hormone regulation. , 1978, Research publications - Association for Research in Nervous and Mental Disease.

[36]  J. Willoughby,et al.  Antiserum to somatostatin prevents stress-induced inhibition of growth hormone secretion in the rat. , 1976, Science.

[37]  J. B. Martin,et al.  Evidence for an endogenous ultradian rhythm governing growth hormone secretion in the rat. , 1976, Endocrinology.

[38]  G. Brown,et al.  Effect of septal lesions on plasma levels of MSH, corticosterone, GH and prolactin before and after exposure to novel environment: role of MSH in the septal syndrome. , 1974, Endocrinology.

[39]  J. B. Martin,et al.  Studies on the mechanism of pentobarbital-induced GH release in the rat. , 1974, Neuroendocrinology.

[40]  J. Letarte,et al.  Effect of stress and hypothalamic deafferentation on the secretion of growth hormone in the rat. , 1973, Neuroendocrinology.

[41]  R. George,et al.  Growth hormone and ACTH secretion: evidence for an inverse relationship in rats. , 1972, Endocrinology.

[42]  D. Kipnis,et al.  Regulation of immunoreactive growth hormone secretion in male rats. , 1971, Endocrinology.

[43]  D. Schalch,et al.  Plasma growth hormone concentration in the rat determined by radioimmunoassay: influence of sex, pregnancy, lactation, anesthesia, hypophysectomy and extrasellar pituitary transplants. , 1966, Endocrinology.